Skip to main content
. 2022 Jun 15;54(1):1657–1666. doi: 10.1080/07853890.2022.2085318

Table 3.

Subgroup analysis of PTB incidence and prevalence in T2DM.

Subgroups N Effect size [95% CI] I2 p Value of between-subgroup heterogeneity
Incidence (per 100,000 person-years)
 Region       <0.01
  Aisa 15 187.20 (147.76, 237.17) 99.3%  
  Europe 3 20.24 (14.64, 27.99) 85.7%  
 TB-burden       0.01
  High 12 172.04 (122.98, 240.68) 99.3%  
  Low 6 73.75 (40.92, 132.91) 99.8%  
 Criteria of PTB       <0.01
  ICD-9 8 203.30 (153.90, 268.55) 98.4%  
  ICD-10 6 73.75 (40.92, 132.91) 99.8%  
  Guidelines for the implementation of China’s TB control Program (2008) 2 85.37 (30.25, 240.87) 95.8%  
  Guidelines for the implementation of China’s TB control Program (2002) 1 119.85 (111.76, 128.53)  
  By reviewing medical or public health records 1 270.00 (218.63, 333.45)  
 Ending year of data collection       <0.01
  ≤2011 10 219.81 (176.15, 274.28) 99.2%  
  >2011 8 66.18 (28.73, 152.47) 99.5%  
Prevalence (per 100,000)
 Region       <0.01
  Aisa 19 594.19 (431.86–817.54) 99.6%  
  Africa 3 617.43 (287.07, 1327.96) 83.5%  
  Europe 2 105.01 (72.55, 151.98) 90.6%  
 TB-burden       <0.01
  High 17 692.15 (468.75, 1022.04) 99.4%  
  Low 7 250.73 (180.22, 348.84) 99.2%  
 Study design       0.89
  Cohort 14 503.19 (339.72, 745.30) 99.8%  
  Cross-sectional 10 524.95 (324.17, 850.07) 90.4%  

PTB: pulmonary tuberculosis; TB: tuberculosis; N: number, CI: confidence intervals.